After Daubert: discerning the increasingly fine line between the admissibility and sufficiency of expert testimony in antitrust litigation
Article Abstract:
Counsel and courts involved in antitrust cases must be aware of the distinction between sufficiency of evidence under the Federal Rules of Civil Procedure and the admissibility of evidence under the Federal Rules of Evidence. Amendments to Rule 26 of the Federal Rules of Civil Procedure and the Supreme Court's decision in Daubert v. Merrill Dow Pharmaceuticals, Inc. have altered the standards applicable to testimony by economic experts. Recent antitrust cases have demonstrated the Supreme Court's willingness to use summary procedures to resolve conflicting economic testimony.
Publication Name: Antitrust Law Journal
Subject: Law
ISSN: 0003-6056
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
The "brave new world" of Daubert: true peer review, editorial peer review, and scientific validity
Article Abstract:
The Supreme Court's ruling in Daubert v. Merrell Dow Pharmaceuticals, Inc. will clarify questions regarding the introduction of scientific evidence under Federal Rule of Evidence 702 by focusing the inquiry on true peer review. Courts have been concerned that the Daubert ruling would require substantial investigations by the court into scientific scholarship. In fact, what Daubert does is focus the standards for scientific evidence on true peer review, a mechanism that is central to scientific inquiry. The new standard will shift the focus from opinions to methodology.
Publication Name: New York University Law Review
Subject: Law
ISSN: 0028-7881
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Supreme Court to rule on scientific testimony in Daubert v. Merrell Dow
Article Abstract:
The US Supreme Court has agreed to hear Daubert v. Merrell Dow Pharmaceutical, a case which should determine the standard of admissibility for scientific expert evidence. The Ninth Circuit, which previously heard the case, adheres to a more restrictive, formalistic standard than other courts. Although the case specifically involves products liability, the ruling could affect the admissibility of any form of scientific evidence.
Publication Name: Law, Medicine & Health Care
Subject: Law
ISSN: 0277-8459
Year: 1992
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: The application of Daubert or Frye analysis to expert testimony in the "soft sciences." Pseudo-economists - the new junk scientists
- Abstracts: Piercing the veil of the limited liability company, from sure bet to long shot. Strict liability for insurers refusing settlements within policy limits: let's quit talking about it and just do it
- Abstracts: Trading claims against Chapter 11 debtors: disclosure as the criterion for the less favorable treatment standard of section 1123(a)(4)
- Abstracts: NAFTA, foreign investment, and the Mexican banking system. The 1993 revision of the Uniform Customs and Practice for Documentary Credits
- Abstracts: AMA advises physicians to screen for signs of abuse. Treatment decisions for terminally ill patients: physicians' legal defensiveness and knowledge of medical law